Signos, a five-year-old startup, is offering an alternative to weight loss drugs by using continuous glucose monitors (CGMs) to provide real-time diet and exercise recommendations. The CGMs, worn on the upper arm, track glucose levels and wirelessly send the information to a smartphone. Signos uses CGMs from Dexcom and its own app to show users how their body responds to specific foods, offering insights into glucose spikes and recommending optimal exercise times for weight loss. The startup recently closed a $20 million funding round led by Cheyenne Ventures and GV (formerly Google Ventures), with Dexcom Ventures also participating. The funds will be used for research into metabolic health and to expand the team.
Signos’ approach aims to attract users committed to a weight-loss journey by offering one-month, three-month, and six-month plans. The six-month plan costs $143 per month and includes the necessary CGMs for that duration. The sensors, such as Dexcom’s G6 and G7, can measure glucose for up to 10 days. Signos is part of a clinical study approved by the US Food and Drug Administration, monitoring biomedical research with Dexcom’s CGMs. The startup focuses on providing personalized recommendations based on glucose data, allowing users to understand the impact of food on their bodies. Users can also integrate sleep, heart rate, and exercise data from their Apple Watch to personalize their profiles further.
Signos CEO Sharam Fouladgar-Mercer, inspired by his own struggles with weight management, created the company to address the missing component in understanding individual metabolism. While diabetes-focused CGMs are the primary focus of companies like Dexcom, they are increasingly being explored for broader applications. Signos aims to leverage data points for non-diabetics and help users make better choices for long-term, sustainable weight management. Fouladgar-Mercer sees the platform complementing weight loss drugs like Ozempic and Wegovy, offering ongoing support for maintaining a healthier lifestyle after the initial phase of using medication.
Read More: https://insightscare.com/
